Skip to main content
Clinical Trials/NCT04681638
NCT04681638
Terminated
Phase 4

Plasma Resuscitation WithOut Lung Injury

Coalition for National Trauma Research6 sites in 1 country13 target enrollmentAugust 17, 2022

Overview

Phase
Phase 4
Intervention
Pathogen-Reduced Plasma
Conditions
Burns
Sponsor
Coalition for National Trauma Research
Enrollment
13
Locations
6
Primary Endpoint
The total volume of all resuscitation fluids delivered between hours 0-24 postern, in ml/kg.
Status
Terminated
Last Updated
last year

Overview

Brief Summary

The treatment of patients with major burns requires resuscitation with massive amounts of fluid, typically a type of salt water that is given by vein. This frequently results in injury to vital organs, especially the lungs and kidneys, and even in death. In this study, the investigators propose to use plasma, a specially prepared blood product made from the liquid part of blood, that has undergone special treatment to reduce the risk of disease transmission. The aims include 1) reduce the amount of fluid given during the first 24 hours after a burn 2) reduce the incidence of lung injury and other complications related to the administration of funds and 3) determine if the blood product has any effect on inflammation. An overall decrease the amount of fluids that burn patients receive should decrease the potential for lung injury, decrease days in the hospital, and improve survival.

Registry
clinicaltrials.gov
Start Date
August 17, 2022
End Date
September 29, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Coalition for National Trauma Research
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age \> 18 years
  • Weight \> 40 kg
  • Initial assessment of thermal injury size ≥ 20% TBSA
  • Admitted to the burn center and enroll able within 8 hours of injury
  • Expected to receive intravenous resuscitation fluids for at least 24 hours after injury
  • Expected to live \> 24 hours after injury

Exclusion Criteria

  • Chemical injury
  • Deep electric injury
  • Associated non-thermal injuries with estimated Injury Severity Score \> 25
  • Inability to obtain informed consent
  • Decision not to treat due to injury severity or other factors
  • Patient age \> 65 years or \< 18 years
  • Presence of anoxic brain injury that is not expected to result in complete recover
  • Patent already receiving plasma infusion, or judged to be likely to require plasma infusion
  • Patent already receiving "rescue procedures" (albumin infusion, CRRT, TPE, or high-dose ascorbic acid)
  • Existence of pre-morbid conditions: Congestive heart failure (NYHA Class IV); End-stage kidney disease (dialysis patient); Cirrhosis of the liver; Oxygen-dependent chronic obstructive pulmonary disease; Malignancy currently under treatment; Previous bilateral lower extremity amputations

Arms & Interventions

Plasma

Pathogen-Reduced Plasma resuscitation

Intervention: Pathogen-Reduced Plasma

Crystalloid

Standardized crystalloid resuscitation

Intervention: Crystalloid Solutions

Outcomes

Primary Outcomes

The total volume of all resuscitation fluids delivered between hours 0-24 postern, in ml/kg.

Time Frame: 24 hours

The total volume of all resuscitation fluids delivered between hours 0-24 postburn, in ml/kg

Secondary Outcomes

  • Metabolic acidosis(48 hours)
  • Total resuscitation volume in ml/kg(48 hours)
  • Total 24 hour resuscitation volume in ml/kg/TBSA(24 hours)
  • Total 48 hour resuscitation volume in ml/kg/TBSA(48 hours)
  • Hemodynamic instability(48 hours)
  • Incidence of "rescue" (b)(48 hours)
  • Incidence of "rescue" (a)(48 hours)
  • Acute Respiratory Distress Syndrome(7 days)
  • Cytokines(48 hours)
  • Mechanical ventilation(28 days)
  • Incidence of "rescue" (c)(24 hours)
  • Intensive Care Unit days(28 days)
  • Multi-Organ Failure Assessment(7 days)
  • Thromboembolic events(7 days)
  • Patient reported outcomes(6 months)
  • Syndecan-1 levels(48 hours)
  • Transfusion-Related Acute Lung Injury(72 hours)
  • Mortality(throughout study completion, an average of 1 year)

Study Sites (6)

Loading locations...

Similar Trials